Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants priority review for Daiichi Sankyo-Merck’s lung cancer therapy
A decision on the drug approval of Daiichi Sankyo-Merck’s lung cancer therapy on June 26 next year. Credit: Merck & Co., Inc., Rahway, NJ USA, and its affiliates.
A decision on the drug approval of Daiichi Sankyo-Merck’s lung cancer therapy on June 26 next year. Credit: Merck & Co., Inc., Rahway, NJ USA, and its affiliates.